21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      EHMTI-0087. Use of oxicodone/naloxone extended release for menstrual migraine

      abstract
      1 , , 1
      The Journal of Headache and Pain
      Springer
      4th European Headache and Migraine Trust International Congress: EHMTIC 2014
      18-21 September 2014

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Menstrual migraine is a big challenge for the migraine expert. Severity and duration of hormonal stimulation determines the gravity and duration of menstrual attack. Various prevention therapy try to alleviate these attacks, usually long half-life triptans and-or anti-inflammatory drugs, combined with caffeine, magnesium, but however is very difficult to find the right drug in particular in women with uterine fibroids or endometriosis. Aims To support this limited class of patients, we considered to use the Oxycodone/Naloxone Extended Release (O/N-ER) for its favourable mechanism of action on neuropathic pain, long half life and well documented gastrointestinal safety. Although the drug has an indication for chronic pain, many reports in literature support its use in acute pain. Methods Recruitment is only for patients non-responders to classical preventive therapy. Will be collected informed consent, headache diary and a satisfaction questionnaire on therapy, those data will compared with the one recorded in the previous quarter, pharmacoeconomic analysis will provided. Patients will use O/N-ER exclusively for menstrual attacks and for three consecutive periods, with the possibility of use a triptan at the start of attack followed by O/N-ER bid for 3-5 days. Results Of the 8 patients that have completed the study (12 patients are ongoing in the trial), 70% of the patients showed a mean reduction in intensity of attacks from 8 to 4 on a NRS scale, grade of satisfaction was 8/10, without significant side effects. More data will come from the analysis of the entire group of the enrolled patients. No conflict of interest.

          Related collections

          Author and article information

          Conference
          J Headache Pain
          J Headache Pain
          The Journal of Headache and Pain
          Springer
          1129-2369
          1129-2377
          2014
          18 September 2014
          : 15
          : Suppl 1
          : G27
          Affiliations
          [1 ]Neurology Department, Giovan Battista Grassi Hospital, Roma, Italy
          Article
          1129-2377-15-S1-G27
          10.1186/1129-2377-15-S1-G27
          4182200
          7fbe79a9-83a2-4c93-877e-5667ea4e117d
          Copyright © 2014 Mostardini and Pauletti; licensee Springer.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

          4th European Headache and Migraine Trust International Congress: EHMTIC 2014
          Copenhagen, Denmark
          18-21 September 2014
          History
          Categories
          Meeting Abstract

          Anesthesiology & Pain management
          Anesthesiology & Pain management

          Comments

          Comment on this article